June 2014. Volume 10. Number 2

Oral risedronate seems to reduce the number of fractures in children with mild osteogenesis imperfecta

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424-32.
Reviewers: Rivas Juesas C1, Rivas Fernández MÁ2.
1Servicio de Pediatría. Hospital de Sagunto. Sagunto. Valencia. España.
2Hospital General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 06/02/2014
Acceptance date: 12/02/2014
Publication date: 23/04/2014

Abstract

Authors' conclusions: oral risedronate increases the bone mineral density and reduces the risk of fractures in children with osteogenesis imperfecta, with good tolerance.

Reviewers' conclusions: oral risedronate could reduce the number of non-vertebral fractures in mild osteogenesis imperfecta, without the high impact in the quality of life and costs of the intravenous treatment. Long term studies are necessary to evaluate the efficacy and safety.

How to cite this article

Rivas Juesas C, Rivas Fernández MA. El risedronato oral parece prevenir las fracturas en niños con osteogénesis imperfecta leve. Evid Peditr. 2013;10:26.

AVC | Critically appraised articles

Bishop N, Adami S, Ahmed SF, Antón J, Arundel P, Burren CP, et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1424-32.
Reviewers: Rivas Juesas C1, Rivas Fernández MÁ2.
1Servicio de Pediatría. Hospital de Sagunto. Sagunto. Valencia. España.
2Hospital General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Cristina Rivas Juesas. Email: crisrijue@hotmail.com
Reception date: 06/02/2014
Acceptance date: 12/02/2014
Publication date: 23/04/2014

How to cite this article

Rivas Juesas C, Rivas Fernández MA. El risedronato oral parece prevenir las fracturas en niños con osteogénesis imperfecta leve. Evid Peditr. 2013;10:26.

References

  1. Steiner RD, Adsit J, Basel D, Pagon RA, Adam MP, Bird TD, et al. COL1A1/2-Related Osteogenesis Imperfecta. GeneReviews™ [Internet]. Seattle (WA): University of Washington; 2005 [updated 2013 Feb 14]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20301472
  2. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfect. Cochrane Database Syst Rev. 2008;4:CD005088.
  3. Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R, Campbell M, et al. A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfect. J Bone Miner Res. 2010;25:32-40.
23/04/2014

Linked Comment